BLACK DIAMOND THERAPEUTICS I (BDTX) Forecast, Price Target & Analyst Ratings

NASDAQ:BDTX • US09203E1055

Current stock price

2.11 USD
-0.04 (-1.86%)
At close:
2.2 USD
+0.09 (+4.27%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BLACK DIAMOND THERAPEUTICS I (BDTX).

Forecast Snapshot

Consensus Price Target

Price Target
$9.31
+ 341.11% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 11, 2026
Period
Q1 / 2026
EPS Estimate
-$0.02
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
84.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$9.31
Upside
+ 341.11%
From current price of $2.11 to mean target of $9.31, Based on 15 analyst forecasts
Low
$6.06
Median
$8.67
High
$13.65

Price Target Revisions

1 Month
0.00%
3 Months
-1.35%

Price Target Summary

15 Wall Street analysts provided a forecast for the next 12 months for BDTX. The average price target is 9.31 USD. This implies a price increase of 341.11% is expected in the next year compared to the current price of 2.11.
The average price target has been revised downward by 1.35% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

BDTX Current Analyst RatingBDTX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

BDTX Historical Analyst RatingsBDTX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10

Analyst Ratings Consensus

ChartMill Buy Consensus
84.00%
BDTX was analyzed by 15 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about BDTX.
In the previous month the buy percentage consensus was at a similar level.
BDTX was analyzed by 15 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-17WedbushMaintains Outperform -> Outperform
2026-01-16Piper SandlerMaintains Overweight -> Overweight
2025-12-04GuggenheimDowngrade Buy -> Neutral
2025-10-16StifelReiterate Buy
2025-09-04GuggenheimInitiate Buy
2025-08-11HC Wainwright & Co.Maintains Buy -> Buy
2025-07-01Raymond JamesReiterate Outperform
2025-03-18HC Wainwright & Co.Maintains Buy -> Buy
2025-03-07StifelMaintains Buy -> Buy
2024-11-06HC Wainwright & Co.Reiterate Buy -> Buy
2024-10-09HC Wainwright & Co.Reiterate Buy -> Buy
2024-10-08WedbushReiterate Outperform -> Outperform
2024-09-24HC Wainwright & Co.Reiterate Buy -> Buy
2024-09-23Piper SandlerMaintains Overweight -> Overweight
2024-09-18HC Wainwright & Co.Reiterate Buy -> Buy
2024-09-10WedbushReiterate Outperform -> Outperform
2024-09-04HC Wainwright & Co.Reiterate Buy -> Buy
2024-08-07WedbushReiterate Outperform -> Outperform
2024-07-31Raymond JamesInitiate Outperform
2024-07-03Piper SandlerMaintains Overweight -> Overweight
2024-06-07HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-16HC Wainwright & Co.Maintains Buy -> Buy
2024-04-08WedbushMaintains Outperform -> Outperform
2024-03-18HC Wainwright & Co.Reiterate Buy -> Buy
2024-03-13WedbushReiterate Outperform -> Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 11, 2026
Period
Q1 / 2026
EPS Estimate
-$0.02
Revenue Estimate
Revenue Q2Q
-100.00%
EPS Q2Q
-101.93%
Number of Analysts
10

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%

Next Earnings Summary

BDTX is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -0.02 USD and the consensus revenue estimate is 0 USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
BDTX revenue by date.BDTX revenue by date.
70M
-100.00%		38.008M126.77M
233.54%		304.07M
139.86%		496.07M
63.14%		670.86M
35.23%
EBITDA
YoY % growth
BDTX ebitda by date.BDTX ebitda by date.
-86.023M
6.82%		-78.438M
8.82%		20.195M
125.75%		-58.616M
-390.25%		-70.394M
-20.09%		-74.955M
-6.48%		-64.882M
13.44%		5.967M
109.20%		103.34M
1,631.86%		154.49M
49.50%		192.04M
24.31%
EBIT
YoY % growth
BDTX ebit by date.BDTX ebit by date.
-86.46M
6.86%		-78.781M
8.88%		19.87M
125.22%		-49.83M
-350.78%		-80.489M
-61.53%		-80.411M
0.10%		-113.976M
-41.74%		-38.566M
66.16%		199.76M
617.97%		356.64M
78.53%		500.65M
40.38%
Operating Margin
BDTX operating margin by date.BDTX operating margin by date.
N/AN/A28.39%N/AN/AN/A-299.87%-30.42%65.70%71.89%74.63%
EPS
YoY % growth
BDTX eps by date.BDTX eps by date.
-1.88
25.40%		-1.27
32.45%		N/A
137.63%		-0.64
-234.45%		-1.00
-55.16%		-0.79
20.41%		-0.57
28.02%		-0.04
92.41%		1.22
2,907.76%		1.98
62.30%		2.40
21.51%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.02
-101.93%		-0.21
-8.90%		-0.21
-39.88%		-0.24
-23.94%		-0.17
-815.46%		-0.18
11.27%		-0.19
7.64%		-0.21
9.02%
Revenue
Q2Q % growth
-100.00%
EBITDA
Q2Q % growth		-14.307M
-126.20%		-14.521M
-9.62%		-14.266M
-33.09%		-15.683M
-57.82%		-18.727M
-30.89%		-20.043M
-38.02%		-21.471M
-50.50%		-23.042M
-46.93%
EBIT
Q2Q % growth		-1.777M
-103.26%		-15.673M
-16.79%		-16.484M
-50.15%		-19.805M
-92.99%		-18.788M
-957.21%		-20.094M
-28.21%		-21.522M
-30.57%		-23.093M
-16.60%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

BDTX Yearly Revenue VS EstimatesBDTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2029 2030 2031 2032 2033 200M 400M 600M
BDTX Yearly EPS VS EstimatesBDTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4 -6

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-54.11%
EPS Next 5 Year
-15.89%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
12.17%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
-84.88%
EBIT Next 5 Year
-19.23%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

BLACK DIAMOND THERAPEUTICS I / BDTX Forecast FAQ

What do analysts expect the price target to be for BLACK DIAMOND THERAPEUTICS I (BDTX)?

15 analysts have analysed BDTX and the average price target is 9.31 USD. This implies a price increase of 341.11% is expected in the next year compared to the current price of 2.11.

What is the next earnings date for BDTX stock?

BLACK DIAMOND THERAPEUTICS I (BDTX) will report earnings on 2026-05-11.

What are the consensus estimates for BLACK DIAMOND THERAPEUTICS I (BDTX) next earnings?

The consensus EPS estimate for the next earnings of BLACK DIAMOND THERAPEUTICS I (BDTX) is -0.02 USD and the consensus revenue estimate is 0 USD.

Can you provide the consensus rating for BLACK DIAMOND THERAPEUTICS I stock?

The consensus rating for BLACK DIAMOND THERAPEUTICS I (BDTX) is 84 / 100 . This indicates that analysts generally have a positive outlook on the stock.